On Invalid Date, Lava Therapeutics Nv (NASDAQ: LVTX) reported Q4 2022 earnings per share (EPS) of -$0.61, up 153.56% year over year. Total Lava Therapeutics Nv earnings for the quarter were -$15.95 million. In the same quarter last year, Lava Therapeutics Nv's earnings per share (EPS) was -$0.24.
As of Q2 2023, Lava Therapeutics Nv's earnings has grown year over year. Lava Therapeutics Nv's earnings in the past year totalled -$34.68 million.
What was LVTX's revenue last quarter?
On Invalid Date, Lava Therapeutics Nv (NASDAQ: LVTX) reported Q4 2022 revenue of $2.81 million up 131.85% year over year. In the same quarter last year, Lava Therapeutics Nv's revenue was $1.21 million.
What was LVTX's revenue growth in the past year?
As of Q2 2023, Lava Therapeutics Nv's revenue has grown 239.31% year over year. This is 169.54 percentage points higher than the US Biotechnology industry revenue growth rate of 69.78%. Lava Therapeutics Nv's revenue in the past year totalled $21.08 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.